Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy ...
December 05 2017 - 05:00PM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, will have updated data from its completed
pilot study1 of NY‑ESO SPEAR T-cell therapy in multiple myeloma
patients in the setting of autologous stem cell transplant (ASCT)
presented at the annual ASH meeting at the Georgia World Congress
Center in Atlanta, Ga.
During an oral presentation, Dr. Edward Stadtmauer,
University of Pennsylvania Abramson Cancer Center, will present an
update on all twenty-five multiple myeloma patients treated in
Adaptimmune’s pilot study in the setting of ASCT. The data cut-off
for the abstract was through July 2017, the data cut-off for the
oral presentation was August 16, 2017.
Oral Presentation 845: Phase I/IIa Study
of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered
Following Autologous Stem Cell Transplant in HLA-a*02+ Patients
with Advanced Multiple Myeloma: Long Term Follow‑up
(NCT01352286)
Session: 703. Adoptive Immunotherapy: Gene
Engineered T cells for Hematologic Malignancies
Time: Monday, December 11, 2017: 5:30 PM
(EST)
Location: Bldg. B, Level 2, B206 (Georgia World
Congress Center)
Result highlights from the abstract include:
- Overall response rate (ORR) at day 100 was 76% (1 stringent
complete response [sCR]; 12 very good partial response [VGPR]; 6
partial response [PR])
- At year 1, 13 patients were progression free (52%) of which 11
were responders (1 sCR; 1 CR; 8 VGPR; 1 PR)
- Three patients remain disease progression-free at 39, 56, and
61 months post T-cell infusion
- Median progression free survival (PFS) was ~13 months (range
3-61 months)
- Eleven of 25 patients (44%) are alive, and median survival was
~35 months (range 6-68 months)
- Autologous GvHD (24%) was reported in 6 patients (3 G3, 3 ≤G2);
all resolved with corticosteroids and supportive therapy
- No fatal adverse events have been reported
About
AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T-cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune is currently conducting
clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP
across several solid tumor indications. GlaxoSmithKline
plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively
license the right to research, develop, and commercialize
Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September
2017. Transition of this program to GSK is ongoing. The Company is
located in Philadelphia, USA and Oxfordshire, U.K. For more
information, please visit http://www.adaptimmune.com
Forward-Looking
StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on November 2, 2017, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
________________________
1 This study closed for enrollment in 2015. All NY-ESO studies
will ultimately transition to GSK as part of its option exercise
over Adaptimmune’s NY‑ESO SPEAR T-cell therapy program that was
announced in September 2017.
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2023 to Mar 2024